Abstract
Background and objectives
The Anaemia Mukt Bharat (AMB) programme advocates for ‘test, treat and track’ strategy. However, limited coverage, poor adherence, workforce shortages and inconsistent follow up, affect implementation. Recent programme monitoring data indicate suboptimal coverage of biweekly iron and folic acid (IFA) supplementation among children aged 6–59 mo, underscoring the need for a standardised, treatment and tracking algorithm. This exercise aimed to develop evidence-based treatment and tracking algorithms for iron deficiency anaemia in children and adolescents (6 mo-18 y) to support clinical decision-making, improve adherence and follow up, and strengthen the AMB programme implementation.
Methods
National/International guidelines and consensus statements were reviewed. Methodological quality was appraised using AGREE II tool. Systematic literature searches were conducted to address specific questions related to diagnostic thresholds for serum ferritin and C-reactive protein (CRP); iron supplementation dosage and frequency; and dosing strategies. Findings were consolidated to develop anaemia management algorithms, refined through expert consultation.
Results
Two algorithms one each for (i) mild, and (ii) moderate—to severe—anaemia were developed. The algorithms included treatment initiation, follow up, response assessment, and guidance to subsequent steps. Measurement of haemoglobin is suggested as the first line test for identification of anaemia, and serum ferritin and CRP for non-responders.
Interpretation and conclusions
The proposed algorithms provide an evidence—based operational approach to strengthen anaemia management and follow up within AMB programme settings to improve continuity of care and reduce variability in practice. These algorithms need field validation in different settings.
Keywords: Adolescents, Anaemia, Children, Treatment
National Family Health Survey-5 (NFHS-5) data indicate that approximately 67% of children under five years of age and 59.1% of adolescent girls are anaemic despite decades of national initiatives for anaemia management.1
India has implemented several large-scale initiatives to address this burden, most recently through the Anaemia Mukt Bharat (AMB) programme. While the programme has expanded screening and treatment coverage, the currently available operational guidance focuses primarily on treatment initiation and periodic haemoglobin assessment. Recent programme monitoring data indicate suboptimal coverage of biweekly iron and folic acid (IFA) supplementation among children aged 6–59 mo, highlighting the need to strengthen implementation, adherence, and follow up mechanisms. Existing literature does not provide any clarity on mechanisms for tracking the beneficiaries till resolution of anaemia, pathway for identification of non-responders, or guidance on when and which additional investigations to be undertaken resulting in fragmented follow up, delayed identification of non-responders, and missed opportunities for etiological evaluation.2
To address these issues, we aimed to develop the treatment and tracking algorithms stratified by severity, designed specifically to address iron-deficiency anaemia (IDA), and inflammation associated non-response pathways for children and adolescents. The rationale for severity-based stratification included clinical risk, urgency of intervention, likelihood of underlying comorbidities, treatment requirements, and monitoring needs as they vary substantially across mild, moderate, and severe anaemia. Children and adolescents with severe anaemia are at greater risk of adverse clinical outcomes, and may require more intensive evaluation, closer follow up, referral, longer duration of treatment, or parenteral therapy, whereas mild anaemia may often be managed effectively at the primary-care level with standard oral iron supplementation and routine monitoring.3,4 Additionally, stratification by severity was considered important from a programmatic perspective to facilitate prioritisation of resources, guide referral pathways, and support stepwise decision-making within the AMB framework. We aimed to translate available scientific evidence and programmatic experience into practical, age- and severity-specific treatment and tracking pathways that could potentially be implemented within the AMB framework.
Methods
Between January 2024 to January 2025, the Indian Council of Medical Research (ICMR) convened a multidisciplinary expert group to review available evidence along with national and international guidelines as a part of extensive review of AMB programme undertaken by ICMR on the directives of NITI Aayog, which led to draft guidelines for AMB 2.0 communicated to Ministry of Health and Family Welfare. The group comprised of paediatricians, haematologists, public health specialists, and nutrition scientists with experience in anaemia control programmes. The group reviewed existing AMB clinical pathways and compared them with relevant national and international guidelines, consensus statements, position papers, and policy documents identified through a focused literature review. Guidelines from the World Health Organization (WHO),5-8 British Society of Haematology (BSH),9 Canadian Paediatric Society (CPS),10 Royal Children’s Hospital Melbourne,11 ESPGHAN/ESPEN/ESPR,12 the Indian Academy of Pediatrics (IAP),13 American Academy of Pediatrics (AAP),14 and Centres for Disease Control and Prevention (CDC)15 were reviewed.
The review process specifically examined domains including screening criteria, haemoglobin and ferritin cut-offs, CRP interpretation, laboratory investigations, treatment regimens, follow up schedules, and referral pathways. The appraisal of guidelines for research and evaluation II (AGREE II) tool16 was used to assess the methodological quality and applicability. Focused literature searches for three specific questions identified during the expert discussions – ferritin and CRP thresholds; timing of iron supplementation; and dosing approaches – were also undertaken. Searches were conducted using predefined terms and limited to full-text articles. The findings were reviewed by two experts and discussed within the expert group before finalising the recommendations.
Based on the combined inputs from guideline mapping, targeted evidence review, and expert deliberation, the proposed age- and severity-specific treatment and tracking algorithms were developed for future pilot testing and phased implementation research.
Results
Review of existing guidelines and recommendations
A comparison of recommendations across key domains such as screening, diagnosis, use of ferritin and inflammatory markers, treatment dosing, and referral is summarised in Supplementary Tables I (A and B). Across these guidelines, some common approaches are evident. Haemoglobin is considered a primary basis for diagnosis of anaemia. The haemoglobin-based severity classification used in the algorithms is presented in Table. Oral iron is suggested as the first-line treatment, and shifting to parenteral therapy or specialist care in severe cases or when response is inadequate.
Table.
Haemoglobin-based severity classification used in the algorithms
| Population group | No anaemia | Mild anaemia (g/dL) | Moderate anaemia (g/dL) | Severe anaemia (g/dL) |
|---|---|---|---|---|
| Children 6–23 mo | ≥10.5 | 9.5-10.4 | 7.0-9.4 | <7.0 |
| Children 24-59 mo | ≥11.0 | 10.0-10.9 | 7.0-9.9 | <7.0 |
| Children 5-11 y | ≥11.5 | 11.0-11.4 | 8.0-10.9 | <8.0 |
| Adolescent boys and girls (12-14 y) | ≥12.0 | 11.0-11.9 | 8.0-10.9 | <8.0 |
| Adolescent girls (15-19 y) | ≥12.0 | 11.0-11.9 | 8.0-10.9 | <8.0 |
| Adolescent boys (15-19 y) | ≥13.0 | 11.0-12.9 | 8.0-10.9 | <8.0 |
Supplementary Tables I (A and B)
At the same time, there is considerable variation in other aspects. Screening approaches differ, IAP13 and AAP14 recommending age-specific or routine screening, while others such as BSH9 and CDC15 favour a more risk-based approach. Guidelines from BSH,9 IAP,13 and ESPGHAN/ESPEN/ESPR12 recommend the use of additional tests such as serum ferritin and C-reactive protein, but the cut-offs used vary across settings. Guidance on follow up lack clarity with limited guidance on response informed management.
Focused review of three key questions
A total of 62 studies were identified for ferritin and CRP thresholds, and 61 studies each for timing of iron supplementation and dosing approaches are summarised in Supplementary Table II. The findings of the focused literature reviews are presented below:
-
(i)
Serum ferritin and CRP thresholds: The review demonstrated variable serum ferritin cut-offs to define iron deficiency. Conventionally, cut-offs of <12–15 µg/L is widely applied; however, recent evidence suggests that higher thresholds may better reflect physiological depletion of iron stores. For example, analysis of NHANES data17 in children aged 12–59 mo estimated a ferritin threshold of ∼19.9 µg/L [95% confidence interval (CI): 18.8–22.6] corresponding to the onset of iron-deficient erythropoiesis. Similarly, population based studies have shown that increasing ferritin cut-offs (e.g., from 12 to 18 µg/L) can lead to a 2-3 fold increase in estimated prevalence of iron deficiency, indicating that lower thresholds may underestimate early deficiency.
CRP was used across studies to interpret ferritin in the context of inflammation; although, uniform CRP adjusted thresholds were not uniformly defined. Most studies18,19 relied on excluding individuals with elevated CRP or interpreting ferritin cautiously in such settings.
-
(ii)
Timing and frequency of oral iron intake: Evidence indicates that iron absorption is influenced by timing of dose, hepcidin regulation, and the degree of IDA.20 Hepcidin levels show a diurnal pattern with higher concentrations in the afternoon than in the mornings. Feedback mechanisms operate to increase the hepcidin levels after iron administration and due to increasing levels of iron in the blood and the liver.21
-
(iii)
Basis of dosing (weight versus age): Guidelines and consensus recommendations are in strong agreement that therapeutic dosing should be weight-based (mg/kg/day). Recommended treatment doses typically range from 2–3 mg/kg/day of elemental iron, with higher doses (up to 6 mg/kg/day) suggested in some cases of severe anaemia.13
Supplementary Tables II
Algorithms
Two treatment and tracking algorithms were developed for IDA in children and adolescents (6 mo-18 y), one each for mild anaemia ( Fig. 1A) and other for moderate-to-severe anaemia ( Fig. 1B). The algorithms are structured as longitudinal care pathways, initiating with IFA supplementation upon diagnosis and extending further to include regular follow up at designated time points, identification of non-responders, and appropriate intervention wherever required until anaemia is resolved.
Fig. 1.

(A) Treatment and tracking algorithm for children (6 mo–18 y) with mild anaemia until resolution. Here, 1Children 6–23 mo: During Measles/MR vaccination (1st and 2nd doses at 9 and 18 mo) or during any health facility visit (if Hb was not checked in the last 12 mo); Children 24–59 mo: During Anganwadi entry or during any health facility visit (if Hb was not checked in the last 12 mo); Children 5–9 y: Once every year through the School Health Programme or during any health facility visit (if Hb was not checked in the last 12 mo); Adolescent boys and girls (10–19 y): Check Once every year at school through the RKSK programme or during any health facility visit (if Hb was not checked in the last 12 mo). 2The range for mild anaemia is similar to that presented in Table. 3Children 6–59 mo (3 mg iron/kg/day for 3 mo): a. 6–12 mo (6–10.9 kg)- 1 ml IFA syrup once daily for 3 mo b. 1-3 y (11–14.9 kg): 1.5 ml IFA syrup once daily for 3 mo; Children 3-5 y (15-19.9 kg): 2 ml IFA syrup once a day for 3mo; Children 5–9 y: One IFA tablet daily for 3 mo (45 mg elemental iron + 400 mcg folic acid); Adolescent boys and girls (10–19 y): One IFA tablets once daily for 3 mo (Each tablet contains 60 mg elemental iron + 500 mcg folic acid) 4Children 6–59 mo: 1 ml IFA syrup twice a wk (Each 1 ml contains 20 mg elemental iron + 100 mcg folic acid); Children 5–9 y: 1 IFA tablet once a wk (Each tablet contains 45 mg elemental iron + 400 mcg folic acid); Adolescent boys and girls (10–19 y): 1 IFA tablet once a wk (Each tablet contains 60 mg elemental iron + 500 mcg folic acid)
Fig. 1.

(B) Treatment and tracking algorithm for children (6 mo–18 y) with moderate and severe anaemia until resolution. Here, 1Children 6–23 mo: During Measles/MR vaccination (1st and 2nd doses at 9 and 18 mo) or during any health facility visit (if Hb was not checked in the last 12 mo); Children 24–59 mo: During Anganwadi entry or during any health facility visit (if Hb was not checked in the last 12 mo); Children 5–9 y: Once every year through the School Health Programme or during any health facility visit (if Hb was not checked in the last 12 mo); Adolescent boys and girls (10–19 y): Check Once every year at school through the RKSK programme or during any health facility visit (if Hb was not checked in the last 12 mo). 2The range for moderate and/or severe anemia is similar to that presented in Table 3Children 6–59 mo (3 mg iron/kg/day for 3 mo): a. 6–12 mo (6–10.9 kg)- 1 ml IFA syrup once daily for 3 mo b. 1-3 y (11–14.9 kg): 1.5 ml IFA syrup once daily for 3 mo; Children 3-5 y (15-19.9 kg): 2 ml IFA syrup once a day for 3mo; Children 5–9 y: One IFA tablet daily for 3 mo (45 mg elemental iron + 400 mcg folic acid); Adolescent boys and girls (10–19 y): One IFA tablets once daily for 3 mo (Each tablet contains 60 mg elemental iron + 500 mcg folic acid). 4Children 6–59 mo: 1 ml IFA syrup twice a wk (Each 1 ml contains 20 mg elemental iron + 100 mcg folic acid); Children 5–9 y: 1 IFA tablet once a wk (Each tablet contains 45 mg elemental iron + 400 mcg folic acid); Adolescent boys and girls (10–19 y): 1 IFA tablet once a wk (Each tablet contains 60 mg elemental iron + 500 mcg folic acid).
Haemoglobin-based classification has been chosen as the starting point,5 the algorithms also advise selective use of additional investigations, like complete blood count (CBC), serum ferritin, and C-reactive protein. in children who do not respond to treatment. Serum ferritin and CRP can help confirm iron deficiency and aid interpretation in the presence of inflammation, while CBC may provide clues to alternative causes of anaemia and guide further evaluation. Ferritin thresholds of: <12 µg/L (<5 y) and <15 µg/L (≥5 y) are recommended to indicate iron deficiency in the absence of inflammation. A serum CRP threshold of less than 5 mg/L, consistent with the WHO guideline22 has been recommended to define absence of inflammation.
In the current algorithm, daily dosing of iron is suggested as the standard approach, consistent with WHO guidelines.8 Also, weight-based dosing is recommended wherever feasible, particularly in clinical settings. At the same time, the algorithms remain compatible with age-based dosing formats used in programme settings to ensure operational feasibility.
It is suggested that each follow up visit should include a review of treatment adherence, along with counselling caregivers for addressing common barriers to iron supplementation before classifying a child as a non-responder.23 The cut off for change in Hb of 1 g/dL has been used to distinguish responders and non-responders.24 After resolution, it is recommended to shift the beneficiary to prophylactic dose.
Discussion
Based on expert evaluation, consensus, and a review of existing guidelines and available evidence, we developed a set of treatment and follow up algorithms for iron deficiency anaemia in children and adolescents (6 mo–18 y). These algorithms are designed to address a key gap in current programmatic guidance: the lack of a structured approach to follow up after treatment initiation. This approach may address gaps in continuity of care, thereby potentially reducing loss to follow up in routine settings. The algorithms are explicitly separated for mild, moderate and severe anaemia, emphasising on higher clinical and functional adverse consequences of moderate anaemia and the need for closer monitoring. The flowchart format allows use as a decision-support tool at the point of care, supporting both clinicians and frontline workers.
Overall, the proposed algorithms are in alignment with other available guidelines, adopting haemoglobin based diagnosis for identification of anaemia, use of oral iron as first line of therapy, and escalation to specialist care in case of severe anaemia or non-responders. However, they differ in their emphasis on structured tracking of beneficiaries as a core component of care. These algorithms provide clear pathway on how and when response is to be evaluated; when additional investigations are required; pathway for non-responders; and follow up till resolution. Further, the inclusion of additional investigations such as ferritin and CRP has been kept selective. Importantly, clinical factors, including dietary history, deworming, recent infections, chronic illness and menstrual history in adolescents should be evaluated before proceeding with investigations such as CRP and ferritin.25,26 CRP could be integrated to screen out individuals with inflammation as it may artifactually raise ferritin, but definitive cut-offs of ferritin in presence of inflammation were not ascertained. As in the presence of elevated CRP, the interpretation of ferritin becomes unreliable due to its acute phase nature, in such cases, the algorithm recommends referral to a specialist for further assessments. This approach ensures that those with potential iron deficiency in context of inflammation are appropriately evaluated. While evidence suggests their usefulness in identifying iron deficiency and interpreting response, their routine use may not be feasible in all settings. Other features that distinguish these algorithms from existing guidance are: severity-based pathways addressing mild and moderate-to-severe anaemia through separate algorithms; structured tracking with clear criteria for follow up intervals and defining response; guidance on management of non-responders, including indications for further investigations and referral; and linkage of treatment with monitoring. Dosing is not presented as a standalone recommendation but is integrated with reassessment and decision-making, ensuring that treatment is guided by response.
Screening, treatment initiation, follow up, and tracking are expected to be undertaken through existing frontline workers and primary healthcare providers, while decisions regarding additional investigations and referral would generally be made at higher-level facilities. Further, the specialist investigations like haematological evaluation, assessment for hemoglobinopathies, micronutrient deficiencies (such as vitamin B12 and folate), chronic infections, inflammatory conditions, and other underlying causes of anaemia, may be undertaken as clinically indicated.
While AMB programme, launched by the Government of India in 2018, has significantly improved the coverage for screening and treatment, especially among pregnant women; the continuity of care still remains a challenge, with lack of clarity on follow up of beneficiaries till resolution of anemia.2 In addition to this, challenges like limited coverage, poor adherence, workforce shortages, inconsistent follow up, and restricted access to diagnostic services affect programme implementation. The proposed algorithms are developed as a framework that can be integrated within existing service delivery platforms of the upcoming AMB 2.0 framework. These should be interpreted as preliminary and hypothesis-generating work rather than as a formally validated guideline. These guidelines require field validation to generate evidence on feasibility, acceptability, operational barriers, and resource requirements to refine the framework before any wider programmatic adoption. The field validation is currently being conducted as a part of the ICMR PRAKASH study.
The effectiveness of these algorithms will depend on implementation factors such as training, availability of diagnostics, and adherence to follow up schedules. Though the proposed approach may increase short-term costs due to follow up and selective investigations, improving identification of non-responders and guiding more targeted management, may enhance cost-effectiveness in the long term. Economic feasibility and cost-effectiveness need to be assessed through pilot implementation studies before scale-up.
शोध-संदेश
अध्ययन में बच्चों और किशोरों में आयरन की कमी से होने वाले एनीमिया के उपचार और निगरानी के लिए एक सरल और प्रमाण-आधारित तरीका सुझाया गया है। एनीमिया में शरीर में पर्याप्त हीमोग्लोबिन नहीं बन पाता, जिससे कमजोरी और थकान जैसी समस्याएं हो सकती हैं। इस अध्ययन में 6 महीने से 18 वर्ष तक के बच्चों और किशोरों के लिए उपचार, दवा के नियमित सेवन और आगे की जांच की निगरानी से जुड़ा एक मानकीकृत तरीका तैयार किया गया। शोधकर्ताओं के अनुसार, यह तरीका एनीमिया के उपचार और मरीजों की नियमित निगरानी को बेहतर बनाने तथा इलाज में होने वाली असमानता को कम करने में मदद कर सकता है। हालांकि, अलग-अलग परिस्थितियों में इसकी उपयोगिता की पुष्टि के लिए इसका व्यावहारिक परीक्षण आवश्यक है।
Acknowledgment
The authors acknowledge Dr Tulika Seth (Professor, Department of Haematology, All India Institute of Medical Sciences, Delhi) and Dr Pankaj Malhotra (Professor and Head, Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh) for their valuable inputs.
Footnotes
How to cite this article: Bansal PG, Chandiok K, Shah D, Chandra J, Kulkarni B, Yadav K, et al. Treatment and tracking algorithm for iron deficiency anaemia among children and adolescents—a policy informed evidence—based framework for India. Indian J Med Res. 2026;164:729-35. doi: 10.25259/IJMR_1502_2026
Author contributions
PGB: Conception and design, supervision of clinical evidence collection and interpretation, manuscript writing, funding acquisition, project administration; KC: Coordination of clinical evidence compilation, interpretation of findings, manuscript writing; DS, JC, BK, KY: Supervised clinical evidence compilation, guidance on the interpretation framework, manuscript writing; KMN, RM: Technical expertise. All authors have read and approved the final printed version of the manuscript.
Financial support and sponsorship
The study received funding support from the Indian Council of Medical Research funds (M15 Meeting Expenditure Head).
Conflicts of Interest
None.
Use of Artificial Intelligence (AI)-Assisted Technology for manuscript preparation
The authors confirm that there was no use of AI-assisted technology for assisting in the writing of the manuscript and no images were manipulated using AI.
References
- 1. International Institute for Population Sciences (IIPS) and ICF. Ministry of Health Family Welfare, Government of India. National Family Health Survey (NFHS-5), 2019–2021, India report. Available from: https://www.dhsprogram.com/pubs/pdf/FR375/FR375.pdf, accessed on March 31, 2026.
- 2. National Health Mission, Ministry of Health Family Welfare, Government of India. Anemia Mukt Bharat Abhiyan operational guidelines. Available from: https://nhm.gov.in/nhm_live/index1.php?lang=1&level=4&lid=804&sublinkid=1455. accessed on March 31, 2026.
- 3.Chami N, Hau DK, Masoza TS, Smart LR, Kayange NM, Hokororo A, et al. Very severe anaemia and one year mortality outcome after hospitalization in Tanzanian children: A prospective cohort study. PLoS One. 2019;14:e0214563. doi: 10.1371/journal.pone.0214563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Pachuta Węgier L, Kubiak M, Liebert A, Clavel T, Montagne A, Stennevin A, et al. Ferrous sulfate oral solution in young children with iron deficiency anaemia: An open-label trial of efficacy, safety, and acceptability. Pediatr Int. 2020;62:820–7. doi: 10.1111/ped.14237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.World Health Organization . Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: WHO; 2024. [PubMed] [Google Scholar]
- 6.World Health Organization . Guideline: Daily iron supplementation in adult women and adolescent girls. Geneva: WHO; 2016. [PubMed] [Google Scholar]
- 7.World Health Organization . Guideline: Intermittent iron supplementation in preschool and school-age children. Geneva: WHO; 2011. [PubMed] [Google Scholar]
- 8.World Health Organization . Daily iron supplementation in infants and children. Geneva: WHO; 2016. [PubMed] [Google Scholar]
- 9.Fletcher A, Forbes A, Svenson N, Wayne Thomas D, A British society for haematology good practice paper Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br J Haematol. 2022;196:523–9. doi: 10.1111/bjh.17900. [DOI] [PubMed] [Google Scholar]
- 10.Unger SL, Fenton TR, Jetty R, Critch JN, O’, connor DL. Iron requirements in the first 2 years of life. Paediatr Child Health. 2019;24:555–6. doi: 10.1093/pch/pxz148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. The Royal Children’s Hospital Melbourne. Clinical Practice Guidelines: Iron deficiency. Available from: https://www.rch.org.au/clinicalguide/guideline_index/iron_deficiency/, accessed on March 31, 2026.
- 12.Domellöf M, Szitanyi P, Simchowitz V, Franz A, Mimouni F, Braegger C. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on paediatric parenteral nutrition: Iron and trace minerals. Clin Nutr. 2018;37:2354–9. doi: 10.1016/j.clnu.2018.06.949. [DOI] [PubMed] [Google Scholar]
- 13.Chandra J, Dewan P, Kumar P, Mahajan A, Singh P, Dhingra B, et al. Diagnosis, treatment and prevention of nutritional anaemia in children: recommendations of the joint committee of paediatric haematology-oncology chapter and paediatric and adolescent nutrition society of the Indian academy of paediatrics. Indian Pediatr. 2022;59:782–801. [PubMed] [Google Scholar]
- 14.Baker RD. Diagnosis and prevention of iron deficiency and iron-deficiency anaemia in infants and young children (0–3 Years of Age) Paediatrics. 2010;126:1040–5. doi: 10.1542/peds.2010-2576. [DOI] [PubMed] [Google Scholar]
- 15.Centres for Disease Control and Prevention Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep. 1998;47:1–36. doi: 10.1037/e547762006-001. [DOI] [PubMed] [Google Scholar]
- 16.Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839–42. doi: 10.1503/cmaj.090449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mei Z, Addo OY, Jefferds ME, Sharma AJ, Flores-Ayala RC, Brittenham GM. Physiologically based serum ferritin thresholds for iron deficiency in children and non-pregnant women: A US national health and nutrition examination surveys (NHANES) serial cross-sectional study. Lancet Haematol. 2021;8:e572–8. doi: 10.1016/S2352-3026(21)00168-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Aabdien M, Al Kaabi N, Al-Kohji SMS, Selim N. Epidemiology of iron deficiency among adolescents aged 10–19 years old in Qatar: A cross-sectional study. BMJ Open. 2022;12:e061666. doi: 10.1136/bmjopen-2022-061666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zikidou P, Tsigalou C, Trypsianis G, Karvelas A, Tsalkidis A, Mantadakis E. Prevalence of anaemia, iron deficiency, iron deficiency anaemia and diagnostic performance of hematologic and biochemical markers of sideropenia in 1- to 5-year-old children in Thrace Greece. Mediterr J Hematol Infect Dis. 2022;14:e2022054. doi: 10.4084/MJHID.2022.054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Stoffel NU, von Siebenthal HK, Moretti D, Zimmermann MB. Oral iron supplementation in iron-deficient women: How much and how often? Mol Aspects Med. 2020;75:100865. doi: 10.1016/j.mam.2020.100865. [DOI] [PubMed] [Google Scholar]
- 21.Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: From discovery to differential diagnosis. Haematologica. 2008;93:90–7. doi: 10.3324/haematol.11705. [DOI] [PubMed] [Google Scholar]
- 22.World Health Organization; Centres for Disease Control and Prevention . Assessing the iron status of populations. 2nd ed. Geneva: WHO; 2007. Report of a joint WHO/CDC technical consultation on the assessment of iron status at the population level. [Google Scholar]
- 23.Powers JM, Nagel M, Raphael JL, Mahoney DH, Buchanan GR, Thompson DI. Barriers to and facilitators of iron therapy in children with iron deficiency anaemia. J Pediatr. 2020;219:202–8. doi: 10.1016/j.jpeds.2019.12.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Okam MM, Koch TA, Tran MH. Iron supplementation, response in iron-deficiency anaemia: Analysis of five trials. Am J Med. 2017;130:e1–991. doi: 10.1016/j.amjmed.2016.06.016. [DOI] [PubMed] [Google Scholar]
- 25.Wiafe MA, Ayenu J, Eli-Cophie D. A Review of the risk factors for iron deficiency anaemia among adolescents in developing countries. Anaemia. 2023;2023:6406286. doi: 10.1155/2023/6406286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lee NH. Iron deficiency in children with a focus on inflammatory conditions. Clin Exp Pediatr. 2024;67:283–9. doi: 10.3345/cep.2023.00521. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Tables I (A and B)
Supplementary Tables II
